Insider Buying: Valeant Pharmaceuticals Intl Inc (VRX) Insider Acquires $32,460,000.00 in Stock

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) insider Valueact Capital Master Fund, bought 3,000,000 shares of the firm’s stock in a transaction dated Tuesday, March 14th. The shares were acquired at an average price of $10.82 per share, with a total value of $32,460,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at 10.64 on Tuesday. The stock’s 50 day moving average price is $13.98 and its 200-day moving average price is $18.38. Valeant Pharmaceuticals Intl Inc has a 52 week low of $10.50 and a 52 week high of $38.50. The stock’s market cap is $3.70 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.06. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.34 billion. During the same quarter in the prior year, the company earned $1.55 EPS. Valeant Pharmaceuticals Intl’s revenue was down 12.9% on a year-over-year basis. Equities analysts anticipate that Valeant Pharmaceuticals Intl Inc will post $3.89 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

var userip;Your IP Address: document.write(userip);

Institutional investors have recently bought and sold shares of the company. Tocqueville Asset Management L.P. raised its position in Valeant Pharmaceuticals Intl by 9.9% in the third quarter. Tocqueville Asset Management L.P. now owns 56,614 shares of the specialty pharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,095 shares during the last quarter. Acadian Asset Management LLC raised its position in Valeant Pharmaceuticals Intl by 127.5% in the third quarter. Acadian Asset Management LLC now owns 425,100 shares of the specialty pharmaceutical company’s stock valued at $10,411,000 after buying an additional 238,216 shares during the last quarter. CIBC Asset Management Inc raised its position in Valeant Pharmaceuticals Intl by 57.9% in the third quarter. CIBC Asset Management Inc now owns 489,967 shares of the specialty pharmaceutical company’s stock valued at $12,024,000 after buying an additional 179,569 shares during the last quarter. Public Sector Pension Investment Board raised its position in Valeant Pharmaceuticals Intl by 3.1% in the fourth quarter. Public Sector Pension Investment Board now owns 522,217 shares of the specialty pharmaceutical company’s stock valued at $7,582,000 after buying an additional 15,900 shares during the last quarter. Finally, Fosun International Ltd raised its position in Valeant Pharmaceuticals Intl by 13.8% in the third quarter. Fosun International Ltd now owns 303,708 shares of the specialty pharmaceutical company’s stock valued at $7,456,000 after buying an additional 36,738 shares during the last quarter. 64.34% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently weighed in on VRX shares. BMO Capital Markets lifted their target price on Valeant Pharmaceuticals Intl to $21.00 in a research report on Wednesday, March 1st. Royal Bank of Canada decreased their price objective on Valeant Pharmaceuticals Intl to $21.00 in a report on Wednesday, March 1st. Guggenheim restated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, February 7th. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price objective on shares of Valeant Pharmaceuticals Intl in a report on Thursday, February 9th. Finally, Jefferies Group LLC decreased their price objective on Valeant Pharmaceuticals Intl from $22.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 1st. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $27.35.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.